Macquarie Group’s Spruce Biosciences SPRB Stock Holding History

Macquarie Group’s Portfolio SPRB Stock Details SPRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5	Closed	–	–	2177
2024 Q1	$0	Buy	+5	New	+$1.27K	﹤0.01%	1959

Other funds holding SPRB

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Macquarie Group's SPRB Position: Q2 2024 in Review

Macquarie Group sold out of Spruce Biosciences (SPRB) in Q2 2024, closing a stake of 5 shares.

Macquarie Group first reported a position in SPRB in Q1 2024 and held it in 1 quarter. The position peaked at $0 in Q1 2024. 37 funds tracked by Wall St. Rank hold SPRB as of Q2 2024.

Macquarie Group reported no remaining Spruce Biosciences position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 5 Spruce Biosciences shares in Q2 2024.
Macquarie Group first reported a position in Spruce Biosciences in Q1 2024 and held it in 1 quarter.
Macquarie Group's Spruce Biosciences position peaked at $0 in Q1 2024.
37 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.